MEROTERPENOID COMPOUNDS FOR USE IN THE PREVENTION AND TREATMENT OF A NEUROLOGICAL DISORDER
The present invention relates to a compound, in particular a meroterpenoid compound, or salt thereof, for use in the prevention and/or treatment of a neurological disorder in an individual. The compound of the invention can promote lactate secretion. A composition comprising the compound of the invention, and a food or food extract enriched with said compound or composition is also provided.
1 . A method for prevention and/or treatment of a neurological disorder in an individual, the method comprising administering to the individual a compound of structural formula (Ia)
wherein R1=H or a halogen;
R2=an isoprenoid chain or a modified isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen; and
R3=H or OH
or a salt thereof.
2 . A method according to claim 1 , wherein the compound has the structural formula
wherein R1=H or a halogen;
R2=an isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen; and
R3=H or OH.
3 . A method according to claim 1 , wherein the compound has a structural formula selected from the group consisting of:
a. Structural formula (Ib)
wherein R1=H or a halogen;
R2=a cyclized isoprenoid chain or a modified cyclized isoprenoid chain and optionally further esterification comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen; and
R3=H or OH;
b. Structural formula (Ic)
wherein R1=H or a halogen;
R2=a cyclized isoprenoid chain with further hydroxylated side chain structure or a modified cyclized isoprenoid chain structure with further hydroxylated side chain structure comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen; and
R3=H or OH; and
c. Structural formula (Id);
wherein R1=H or a halogen;
R2=an open isoprenoid chain or a modified open isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen; and
R3=H or OH.
4 . A method for prevention and/or treatment of a neurological disorder in an individual, the method comprising administering to the individual a compound of structural formula (II)
wherein R1=phenethyl or a modified phenethyl side chain, and/or an isoprenoid chain or a modified open isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen;
R2=H or an isoprenoid chain or a modified open isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen;
R3=H or methyl, and
R4=an isoprenoid chain or a modified open isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen
or a salt thereof.
5 . A method for prevention and/or treatment of a neurological disorder in an individual, the method comprising administering to the individual a compound of structural formula (III)
wherein R1=an isoprenoid chain or a modified open isoprenoid chain comprising 1 to carbon atoms, hydrogen, and optionally oxygen
R2=H or OH
or a salt thereof.
6 . A method according to claim 3 , wherein the compound has structural formula (Ib).
7 . A method according to claim 6 , wherein R1=Cl, and R3=H.
8 . A method according to claim 6 , wherein the compound is ascochlorin.
9 . A method according to claim 6 , wherein the compound is CAS 22562-67-0 (Illicicolin C).
10 . A method according to claim 6 , wherein the compound is CAS 22738-98-3 (Illicicolin F).
11 . A method according to claim 1 , wherein lactate secretion is promoted.
12 . A method according to claim 1 , wherein the lactate secretion from astrocytes is promoted.
13 - 22 . (canceled)